Ensysce raises $2.2M via warrant exercise inducement; issues new warrants for 1.26M shares

Ensysce Biosciences, Inc.

Holders exercised 630,376 warrants at $3.24/share for cash; gross proceeds ~$2.2M before fees.
Company issued new unregistered warrants to purchase 1,260,752 shares at $1.90, split 18-month and 5-year terms.
Net proceeds ~$1.9M to fund TAAP and MPAR programs and working capital.
H.C. Wainwright acted as placement agent; received 7% cash fee and 44,126 agent warrants at $4.05.
New warrants include 4.99% beneficial ownership limitation (9.99% at holder election).

item 1.01 item 3.02 item 8.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001641172-25-006009
form_type: 8-K
ticker: ENSC
cik: 0001716947
company_name: Ensysce Biosciences, Inc.
filed_at: 2025-04-24T23:59:59+00:00
discovered_at: 2026-05-14T18:02:49.454853+00:00
generated_at: 2026-05-23T07:08:24.857177+00:00
sec_items: ["1.01", "3.02", "8.01", "9.01"]
event_type: other_material
sentiment: neutral
materiality_score: 0.65
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001641172-25-006009
json_url: https://secwatch.observer/filing/0001641172-25-006009.json
markdown_url: https://secwatch.observer/filing/0001641172-25-006009.md
text_url: https://secwatch.observer/filing/0001641172-25-006009.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1716947/000164117225006009/0001641172-25-006009-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1716947/000164117225006009/form8-k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001641172-25-006009

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.